Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 2

Sponsor Class

INDUSTRY 352OTHER 60OTHER_GOV 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 267Neoplasms 177Colorectal Neoplasms 133Stomach Neoplasms 107Uterine Cervical Neoplasms 96Carcinoma, Non-Small-Cell Lung 89Prostatic Neoplasms 83Lung Neoplasms 78Carcinoma, Hepatocellular 73Rectal Neoplasms 64Ovarian Neoplasms 54Esophageal Neoplasms 53Pancreatic Neoplasms 52Colonic Neoplasms 52Recurrence 43Multiple Myeloma 39Neoplasm Metastasis 38Head and Neck Neoplasms 37Endometrial Neoplasms 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Motor Activity 34Melanoma 33Polycystic Ovary Syndrome 32Lymphoma 32Urinary Bladder Neoplasms 31Leukemia, Myeloid, Acute 30Thyroid Neoplasms 29Small Cell Lung Carcinoma 28Nasopharyngeal Carcinoma 25Lymphoma, Non-Hodgkin 25

Interventions

spartalizumab 1pembrolizumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Advanced Solid Tumor × Clear all
NCT04268108 2020-06-11

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Henan Cancer Hospital

Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡